The first affordable, one-click bacterial genomics analysis platform. Upload your FASTQ. Get publication-ready results. No bioinformatics degree required.
🇨🇦 Built in Canada · ☁️ Cloud-Native · 🧬 Research-Grade
01 · Vision & Mission
Democratizing Bacterial Genomics
Making genome analysis accessible to every lab, every researcher, everywhere — regardless of their computational skills.
🔬
The Problem
Sequencing costs dropped from $500 to $30/sample. But analysis still requires bioinformatics expertise, Linux servers, and 2+ hours of manual work. The analysis bottleneck is the new barrier to microbial genomics.
💡
Our Solution
A web platform where any scientist can upload raw FASTQ files and receive publication-ready PDF reports with 8+ charts, data packages, and actionable insights — in 30 minutes, for $5-25/sample.
🎯
Our Vision
Become the "Canva of microbial genomics" — not the most powerful tool, but the most accessible one. We don't compete with Photoshop. We compete with confusion.
02 · What We Built
Current Platform — Live & Working
A fully operational end-to-end bacterial WGS pipeline deployed at bioanalysis.ca.
Shotgun metagenomics — community profiling with Kraken2 + MetaPhlAn
Fungal ITS sequencing support
API access for programmatic batch submission
Team/lab accounts with shared projects
Phase 5 — 12 Months
Enterprise & Clinical
White-label solution for hospital networks
LIMS integration (laboratory info management)
Audit trails and compliance reporting
On-premises deployment option
Custom report templates per client
04 · Competitive Advantages
Why BioAnalysis.ca Wins
Six unique advantages that no competitor can match today.
🚀
FASTQ → PDF in One Click
Upload raw FASTQ, get polished PDF. No command line, no Docker, no Linux server. Nobody else does this.
📊
8 Publication-Ready Charts
Species donut, AMR heatmap, QC bars, assembly radar, contig histogram, Nx plot, gene features, GC distribution — all in one report.
📦
Research Data Package
Downloadable ZIP with CSV data, raw output files (FASTA/GFF/TSV), and all charts as high-res PNGs for publications.
💰
10x Cheaper
$5-25/sample vs CosmosID ($50-100/sample) or CLC Genomics ($3K-6K/year). Accessible to grad students.
🎨
Modern UI/UX
Dark-mode, real-time progress, mobile responsive. Competitors look like they were built in 2005. We look like 2026.
🇨🇦
Canadian & PIPEDA
Data stays in Canada. No US data transfers. Appeals to Canadian universities, provincial labs, and PHAC.
❌ What free tools give you
Raw text output files
Need 3-5 different tools combined
2+ hours of manual work
Ugly data tables, no charts
No support — "read the docs"
"Figure it out yourself"
2005-era interfaces
✅ What BioAnalysis.ca gives you
Beautiful publication-ready PDF
One-click upload, fully automated
30 minutes, zero effort
8 scientific charts included
Email support + help docs
"We handle everything"
Modern dark-mode UI, mobile ready
05 · Competitive Landscape
Who We're Up Against
7 competitors analyzed. None offers the complete FASTQ-to-PDF experience.
Feature
Pathogen Watch
BV-BRC
Entero Base
CLC
CosmosID
Bactopia
BioAnalysis.ca ⭐
Price
Free
Free
Free
$3K+/yr
$50+/s
Free
$5-25
Raw FASTQ
✕
✓
✓
✓
✓
✓
✓
Assembly
✕
✓
✓
✓
✕
✓
✓
AMR
✓
✓
✕
✓
✓
✓
✓
PDF Report
✕
✕
✕
⚠
✓
✕
✓
Data ZIP
✕
✕
✕
⚠
✓
✓
✓
Charts
✕
⚠
✓
✓
✓
✕
8 charts
No Coding
✓
⚠
✓
✓
✓
✕
✓
Modern UI
⚠
✕
✕
⚠
✓
✕
✓
Mobile
✕
✕
✕
✕
⚠
✕
✓
Platform Capability Radar
06 · Market Opportunity
Why This Market, Why Now
The analysis bottleneck is the new frontier. Sequencing got cheap. Analysis didn't.
$20B
Total Genomics Market
$50M
Bacterial SaaS Gap
0
Dominant Player
100K+
WGS Samples/Year
Where the Money Flows (Genomics $20B Market)
Sequencing HW
$4.0B
Reagents
$3.5B
Library Prep
$2.0B
Seq Services
$1.5B
Clinical Dx
$1.0B
Bacterial SaaS
$50M
Why is it only $50M? Because governments built free tools (BV-BRC, PathogenWatch), the academic culture favors "build, not buy," and the total number of bacterial genomics labs (~5,000 worldwide) creates a small TAM. But the market is growing 30%+ annually as sequencing costs drop.
Why No Big Player Entered This Space
🆓
Free Government Tools
NIH spends $5M/year on BV-BRC alone. Hard to compete with "free" — but you CAN compete on UX.
🎓
Academic "Build Not Buy"
Researchers trained to use CLI. Paying for analysis seen as "lazy." But 90% of wet-lab scientists can't code.
💵
Small TAM for VCs
$50M market too small for VC-backed startups ($100M+ needed). Perfect for a lean bootstrapped company.
🧩
Fragmented Needs
Every lab studies different bacteria. Hard to build one-size-fits-all. Solution: start with core WGS, expand modularly.
The window is NOW. Sequencing dropped from $500 to $30/sample. Thousands of new labs adopted WGS since COVID. They all need fast, easy analysis. The gap between "free & ugly" and "enterprise & expensive" is wide open.
07 · Target Customers
Who Will Pay & How Much
Six distinct customer segments with different needs and willingness to pay.
🔬
Wet-Lab Scientists
$10–25 / sample
Can't use command line. Thesis deadline looming. Need results NOW. Will happily pay for convenience and publication-ready charts.
Annual contracts with hospital networks, public health agencies. $10K-50K/year per contract.
Phase 5
🔌
API Access
Programmable API for CROs and bioinformatics companies. $0.50-2/API call for headless pipeline execution.
Phase 4
🏷️
White Label
Branded platform for sequencing companies and hospitals. License fee: $20K-100K/year.
Phase 5
09 · Funding Opportunities
Where to Get Money
Multiple Canadian and international funding sources for biotech startups and health-tech innovation.
🇨🇦
IRAP (NRC)
Up to $1M — Non-dilutive
National Research Council's Industrial Research Assistance Program. Funds innovative SMEs. Covers salaries, contractor costs. Perfect fit for health-tech.
💼
SR&ED Tax Credits
35-65% of R&D costs returned
Scientific Research & Experimental Development credits. Claim your pipeline development, chart generation, and infrastructure work. Refundable for CCPCs.
🏦
BDC (Business Development Bank)
$50K-5M — Loans + equity
Government-backed bank for tech startups. Patient capital, lower rates than commercial banks. Tech-specific programs.
🎓
Mitacs / Academic Partnerships
$15K-60K per intern/year
Co-fund graduate students working on your platform. University partner does research, you get subsidized labor and academic credibility.
🌐
Genome Canada
$100K-2M — Research grants
Funds genomics innovation in Canada. Your platform directly aligns with their mission of making genomics accessible.
🏆
Alberta Innovates
$25K-500K — Vouchers + grants
Province-specific innovation funding. Digital Health, Cleantech, and AI programs. Strong fit for Edmonton/Calgary-based companies.
🚀
Y Combinator / Techstars
$125K-500K — Equity (7%)
Top accelerators. YC's bio track accepts health-tech startups. 3-month program + demo day access to 1000+ investors.
💰
Angel Investors (Biotech)
$25K-250K — Equity
Life science angels understand genomics. Target groups: Life Sciences BC, MaRS Health Venture network, BioAlberta.
Bootstrap-first strategy recommended. With 95%+ margins and low compute costs, you can reach $50K+ ARR before needing external funding. Use SR&ED credits and IRAP to fund development. Only raise equity once you have product-market fit with paying customers.
10 · Sequencing Types — Expansion Plan
From WGS to Full Microbial Platform
Each sequencing type has different tools, compute needs, and market size.
Type
Tools
RAM
Time
VPS Cost
Market
Difficulty
Status
Bacterial WGS
SPAdes, Bakta, AMRFinder
16-32 GB
30-180 min
$0.15
Medium
Done
✅ LIVE
16S rRNA
QIIME2, DADA2, SILVA
4-8 GB
5-20 min
$0.02
HUGE
Medium
🔜 NEXT
Viral WGS
Nextclade, Pangolin
4 GB
2-10 min
$0.01
Medium
Easy
Phase 4
Shotgun Metagenomics
Kraken2, MetaPhlAn
16 GB
15-45 min
$0.10
Growing
Medium
Phase 4
Fungal ITS
ITSx, UNITE
4-8 GB
5-15 min
$0.02
Niche
Easy
Future
Human WGS
BWA, GATK
64-256 GB
6-24 hrs
$2-10
Huge
Very Hard
❌ AVOID
Human WGS is avoided intentionally. It requires PIPEDA/HIPAA compliance ($100K+), ethics board approval, 100GB storage per sample, and carries legal liability. The risk-reward is not worth it for a startup. Stay in microbial genomics.
11 · Risks & Mitigations
Honest Risk Assessment
Every business has risks. Here's how we address ours.
⚠ Risk: Free tools improve their UX
NIH could modernize BV-BRC with a beautiful interface, eliminating our UX advantage.
Mitigation: Government moves slowly. Our moat is speed of iteration. Stay 2+ years ahead in UX. Add features (batch, phylo) they don't offer.
⚠ Risk: Low willingness to pay
Researchers won't switch from free tools to paid. Academic budgets are tight.
Mitigation: Target non-academic segments (food safety, clinical) who MUST have fast results. Offer free tier for students to build adoption funnel.
⚠ Risk: Pipeline accuracy concerns
Researchers don't trust "black box" analysis. They want to see exact tools and parameters.
Mitigation: Full transparency: list exact tool versions, parameters, and database versions in every report. Open-source the pipeline code.
⚠ Risk: Big player enters market
Illumina, QIAGEN, or Oxford Nanopore launches a competing free/bundled analysis tool.
Mitigation: Build strong customer relationships and brand loyalty quickly. Position for acquisition — being bought by Illumina IS a valid exit.
12 · Bottom Line
Why This Will Work
Market exists?
Yes — $50M+ and growing 30%/yr
Can we make $?
Yes — 95% margins, low costs
Competition?
Surprisingly low — gap is wide open
Exit possible?
Yes — Illumina/QIAGEN acquire tools
🧬
"Upload your FASTQ. Get your results. No bioinformatics degree required."
The gap between "free & ugly" and "enterprise & expensive" is wide open. BioAnalysis.ca is filling it.